Clarity Pharmaceuticals (ASX:CU6) adds leading cancer expert to SAB, shares jump

Image Source: © Rawpixelimages |


  • CU6 has welcomed Prof Emmett, a leading cancer research expert, to its Scientific Advisory Board.
  • Prof Emmett is committed to aiding the company in developing novel radiopharmaceuticals.
  • She is heavily involved in Australia’s multidisciplinary clinical development and cancer research efforts.

Clarity Pharmaceuticals (ASX:CU6) has bolstered its Scientific Advisory Board (SAB) with the addition of a leading nuclear medicine and theranostics expert. The clinical-stage radiopharmaceutical company has appointed Professor Louise Emmett to the SAB.

Prof Emmett has been the company’s long-term collaborator. She has aided the company in swiftly advancing Phase I studies in breast and prostate cancers, backed by her in-depth knowledge of the radiopharmaceutical space and expertise in navigating the early-stage clinical trial scene in Australia.

CU6 share price up 11%

CU6 shares saw a significant jump in its share price post the update. The shares rallied by over 11% to AU$0.545 midday on 29 June 2022. The company has a market capitalisation of AU$126.38 million.

In the last one month, the stock has delivered a return of more than 9%.

About Professor Louise Emmett

Prof Emmett has a huge role in advancing SAR-Bombesin and SAR-bisPSMA products. Earlier this month, she presented data from the pilot diagnostic trial of SAR-Bombesin in breast cancer at the 2022 Annual Meeting of the reputed American Society of Clinical Oncology (ASCO).

Additionally, she has successfully imaged several prostate cancer patients who are PSMA-negative under a Special Access Scheme in Australia, laying a foundation for Clarity's lately approved US-based Phase II trial with SAR-Bombesin in this indication. Moreover, she is offering her services to several potential randomised studies as a principal investigator.

Prof Emmett current roles (source: company update)


Prof Emmett secured a degree in 2014 from Auckland University as a Doctor of Medicine in Nuclear Cardiology.

Besides obtaining several clinical research grants, she has been a part of peer-reviewed journals, contributing more than 100 original papers in the last one decade.

She is looking forward to continuing her collaboration with Clarity, now as a member of the SAB, to develop novel radiopharmaceuticals to improve treatment outcomes for cancer-affected children and adults.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and